218 related articles for article (PubMed ID: 36158591)
1. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
Gigante E; Hobeika C; Le Bail B; Paradis V; Tougeron D; Lequoy M; Bouattour M; Blanc JF; Ganne-Carrié N; Tran H; Hollande C; Allaire M; Amaddeo G; Regnault H; Vigneron P; Ronot M; Elkrief L; Verset G; Trepo E; Zaanan A; Ziol M; Ningarhari M; Calderaro J; Edeline J; Nault JC
Liver Cancer; 2022 Sep; 11(5):460-473. PubMed ID: 36158591
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Kim EJ; Yoo C; Kang HJ; Kim KP; Ryu MH; Park SR; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY
Liver Int; 2021 Jun; 41(6):1398-1408. PubMed ID: 33548073
[TBL] [Abstract][Full Text] [Related]
3. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
4. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
7. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
[TBL] [Abstract][Full Text] [Related]
9. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
Pomej K; Balcar L; Shmanko K; Welland S; Himmelsbach V; Scheiner B; Mahyera A; Mozayani B; Trauner M; Finkelmeier F; Weinmann A; Vogel A; Pinter M
ESMO Open; 2023 Feb; 8(1):100783. PubMed ID: 36753993
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.
Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P
J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma.
Yang X; Chang J; Li R; Qi Y; Zeng X; Wang W; Li H
J Hepatocell Carcinoma; 2023; 10():113-122. PubMed ID: 36727035
[TBL] [Abstract][Full Text] [Related]
14. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in the Setting of Cirrhosis.
De Martin E; Rayar M; Golse N; Dupeux M; Gelli M; Gnemmi V; Allard MA; Cherqui D; Sa Cunha A; Adam R; Coilly A; Antonini TM; Guettier C; Samuel D; Boudjema K; Boleslawski E; Vibert E
Liver Transpl; 2020 Jun; 26(6):785-798. PubMed ID: 32090444
[TBL] [Abstract][Full Text] [Related]
16. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma.
Zhou C; Lu X; Wang Y; Qian X; Yang C; Zeng M
Eur Radiol; 2022 Oct; 32(10):6702-6711. PubMed ID: 35976399
[TBL] [Abstract][Full Text] [Related]
17. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
19. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]